Published on March 19, 2010 at 2:19 AM
Medtronic, Inc. (NYSE:MDT) today announced that a landmark publication
highlighting results from the pivotal study for Medtronic Deep Brain
Stimulation (DBS) Therapy for epilepsy, known as SANTE® (Stimulation of
the Anterior Nucleus of the Thalamus in Epilepsy), was published online
today in the medical journal, Epilepsia. The SANTE study,
sponsored by Medtronic, is the largest and most rigorous clinical study
of DBS therapy for epilepsy in adults with medically refractory epilepsy
with partial-onset seizures. Today’s publication includes results from
the blinded phase of the study and through two years of therapy.
Medtronic DBS therapy is under review by the U.S. Food and Drug
Administration (FDA).
“The SANTE trial was a rigorous, well-designed, blinded trial with
long-term follow up in an open-label phase. Based on the outcome of the
study, DBS therapy holds promise for patients with epilepsy who are
severely affected and have not had success with other treatments”
“The SANTE trial was a rigorous, well-designed, blinded trial with
long-term follow up in an open-label phase. Based on the outcome of the
study, DBS therapy holds promise for patients with epilepsy who are
severely affected and have not had success with other treatments,” said
Robert Fisher, M.D., professor of neurology and director of Stanford
Epilepsy Center, principal investigator for the SANTE study and lead
author of today’s publication.
Source Medtronic, Inc.